MedTrace Logo

Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin

NCT01304329 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2014-07-28

Study results available
· View outcomes & findings →

Summary

The objective of the study is to investigate the drug-drug interaction potential between BI 10773 and simvastatin.

Conditions

  • Healthy

Interventions

DRUG

BI 10773

Medium dose oral administration

DRUG

simvastatin

Medium dose oral administration

DRUG

simvastatin

Medium dose oral administration

DRUG

BI 10773

Medium dose oral administration

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01304329 on ClinicalTrials.gov